The Food and Drug Administration is asking Eli Lilly to gather more safety data on its new weight loss pill, Foundayo, ...

Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...

On April 1, Eli Lilly (NYSE: LLY) and its shareholders received the news they were eagerly awaiting: the approval of the company's GLP-1 pill, Foundayo. While the company isn't the first out of the ...

Preview this article 1 min CrossBridge Bio is developing unique methods to transport chemotherapy to cancer cells, and its ...

CrossBride Bio is developing a dual-payload cancer drug expected to begin human trials in 2026. ・The U.S. Food and Drug ...

CrossBridge Bio, a privately held biotech focused on developing cancer drugs, announced on Tuesday an agreement to be acquired by Eli Lilly (LLY) in an all-cash deal worth up to $300M. The ...

The U.S. ‌Food ‌and Drug Administration ​said Eli Lilly is required ‌to ⁠conduct post-marketing trials ⁠to gauge risks ​for ...

The Federal Drug Administration (FDA) has approved a new once-daily weight-loss pill from Eli Lilly, adding to the bevy of ...

Eli Lilly has rolled out Foundayo, its oral GLP-1 pill, directly to consumers through its LillyDirect cash-pay channel, as ...

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug.

Amazon will offer delivery of Eli Lilly's new weight-loss pill Foundayo and stock it at kiosks at some of the company's ...

Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price ...